Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

New Interleukin-12/23 Monoclonal Antibody Effective Against Moderate to Severe Psoriasis: Presented at EADV By Jenny Powers BERLIN -- October 12, 2009 -- Patients with moderate to severe psoriasis experienced disease control following treatment with a new interleukin-12/23 monoclonal antibody known as ABT-874, researchers noted here at the 18th Congress of the European Academy of Dermatology and Venereology (EADV). ABT-874 offered disease control regardless of age, weight, gender, previous treatment history, the presence of psoriatic arthritis, or disease severity. Even patients with severe psoriasis achieved a score of 75 on the Psoriasis Area and Severity Index (PASI) within 12 weeks of treatment. Richard Langley, MD, Dalhousie University, Halifax, Nova Scotia, reported these findings here on October 8 regarding the efficacy of ABT-874. The study explored the effect of baseline characteristics of patients with moderate to severe psoriasis on the efficacy of ABT-874. The 12-week, randomised, double-blind, placebo-controlled, multicentre study enrolled 180 adults, all of whom had psoriasis affecting at least 10% of their body surface area and a PASI score of 12 or greater. The subjects were randomised into 1 of 6 treatment arms: 1. 200 mg ABT-874 at week 0 2. 100 mg ABT- 874 every other week for 12 weeks 3. 200 mg ABT-874 weekly for 4 weeks 4. 200 mg ABT-874 every other week for 12 weeks 5. 200 mg ABT-874 weekly for 12 weeks or 6. Placebo The aim of the study was to determine the effects of psoriatic arthritis history, PASI score, previous psoriasis treatments, and Physician’s Global Assessment (PGA) score (severe/very severe) on achieving PASI 75 at week 12 following treatment with ABT-874. ABT-874 was effective at all dose levels; 86% of all ABT-874-treated patients achieved PASI 75 at week 12 versus 3% in the placebo group. Additionally, no patients in the placebo group achieved PASI 90 compared with 53% of all ABT-874-treated patients. Regarding weight characteristics, the percentage of patients achieving PASI 75 at week 12 in the 100 kg-or-less category was 88.7% versus 81.1% in the over-100 kg group. The PASI 75 responses for patients with and without psoriatic arthritis were 83.7% versus 86.9% respectively, and 85.5% of patients with a PGA score of severe or very severe at baseline achieved PASI 75. Eighty-seven percent of patients with baseline PASI scores of 20 or less achieved PASI 75 responses at week 12, compared with 84% whose baseline PASI scores were greater than 20. Prior psoriasis therapies -- using either systemic or biologic agents, topicals, or phototherapy -- had no effect on the PASI 75 response rates achieved with ABT-874. ABT-874 was well tolerated. Funding for this study was provided by Abbott Laboratories. [Presentation title: Effect of Baseline Characteristics on the Efficacy of ABT-874 for the Treatment of Moderate to Severe Psoriasis. Abstract P1197] E-mail this page to a friend or colleague! To print, use this version